Mature results from Hoosier Oncology Group GU04-75 phase II trial of cisplatin (C), gemcitabine (G), and bevacizumab (B) as first-line chemotherapy for metastatic urothelial carcinoma (UC).

Bladder Cancer in 2010: How Far have We Come?

“…224 A phase 2 study of bevacizumab in combination with cisplatin and gemcitabine in metastatic or locally advanced bladder cancer involving 36 patients showed a complete response in 6 (17%), and a partial response in 18 (50%); this combination is now being studied in a phase 3 trial. 123,225 Another phase 2 study involving trastuzumab (Herceptin), which is an antibody to HER-2, has been evaluated in metastatic or locally advanced bladder cancer patients with HER-2 expression in combination with chemotherapy; responses were seen in 70% of patients (5 complete and 26 partial responses). 123,226 Postchemotherapy surgery in patients with unresectable or metastatic disease may impact survival.…”

A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma

“…[14][15][16][17][18][19][20][21] Clinical studies in UC with antiangiogenic agents have shown antitumor activity. [22][23][24][25][26] Although these studies validate the potential for an antiangiogenic approach to UC, they also indicate the need to investigate alternative ways to target the tumor vasculature. Directly targeting proliferating endothelial cells, a major component of tumor vasculature, by modifying CD105 signaling is a unique mechanism of targeting angiogenesis.…”

Personalized therapy for urothelial cancer: review of the clinical evidence

“…In addition, VEGFR and EGFR inhibition may sensitize to cisplatin [26,27]. Hahn et al recently reported the mature results of their phase II study of bevacizumab with cisplatin and gemcitabine as first-line therapy for metastatic urothelial carcinoma [28] (Table 1). The overall response rate was 72% with 9 complete responses and 22 partial responses out of 43 patients.…”